March 31st 2025
Urcosimod (formerly known as OK-101) has been shown to be stable for over 2 and a half years in single-use ampoules used for administration of the drug to patients.
Navigating the Advances in the Treatment of Geographic Atrophy: Updates and Strategies for Managed Care
View More
CRU Eye Symposium
March 28-30, 2025
Register Now!
Eye Care Symposia in Los Angeles
April 25-26, 2025
Register Now!
Community Practice Connections™: Optimizing Outcomes in Glaucoma Management - Applying Evidence to Practice with a Multitude of Treatment Options (CME Track)
View More
Community Practice Connections™: Mastering the New Treatment Paradigm in Geographic Atrophy – From Detection to Intervention (CME Track)
View More
Assessing the Evidence for Extending Treatment Intervals in nAMD and DME Management – Expert Insights into Innovative Approaches (CME Track)
View More
Assessing the Evidence for Extending Treatment Intervals in nAMD and DME Management – Expert Insights into Innovative Approaches (COPE Track)
View More
Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics (CME Track)
View More
Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics (COPE Track)
View More
Surv.AI Says: Real-World Insights Into Patient Burden & Evolving Strategies in nAMD and DME (CME Credit)
View More
Surv.AI Says: Real-World Insights into Patient Burden & Evolving Strategies in nAMD and DME (COPE Credit)
View More
Community Practice Connections™: Mastering the New Treatment Paradigm in Geographic Atrophy – From Detection to Intervention (COPE Track)
View More
Community Practice Connections™: Optimizing Outcomes in Glaucoma Management - Applying Evidence to Practice with a Multitude of Treatment Options (COPE Track)
View More
Reimagining Dry Eye Disease: Delineating the Role of Evaporation From Inflammation and Insights Into Optimizing Treatment (CME Track)
View More
Reimagining Dry Eye Disease: Delineating the Role of Evaporation From Inflammation and Insights Into Optimizing Treatment (COPE Track)
View More
19th Annual Controversies in Modern Eye Care
May 4, 2025
Register Now!
(CME Track) Community Practice Connections™: Advancing the Optimal Diagnosis & Treatment of Thyroid Eye Disease
View More
(COPE Track) Community Practice Connections™: Advancing the Optimal Diagnosis & Treatment of Thyroid Eye Disease
View More
(CME) Community Practice Connections™: A Closer Look at Neurotrophic Keratitis—Ensuring Timely Diagnosis and Taking Early Action
View More
Outlining the New Standard in Geographic Atrophy: Optimizing Care Within the Modern Treatment Paradigm (CME Track)
View More
Outlining the New Standard in Geographic Atrophy: Optimizing Care Within the Modern Treatment Paradigm (COPE Track)
View More
Collaborative Care Symposium
May 30-31, 2025
Register Now!
Community Practice Connections™: Novel Therapies for Neovascular Retinal Disease – Expert Analysis of New Key Data
View More
Latest Advances in X-Linked Retinitis Pigmentosa: Optimizing Diagnosis and Developments in Gene Therapy
View More
Cases & Conversations™: Real World Review of Treat and Extend Strategies for Neovascular Retinal Disease
View More
Community Practice Connections™: Innovations and Interdisciplinary Approaches in Glaucoma Management—Expanding the Treatment Arsenal (CME Track)
View More
Community Practice Connections™: Innovations and Interdisciplinary Approaches in Glaucoma Management—Expanding the Treatment Arsenal (COPE Track)
View More
Road Mapping the Treat-and-Extend Protocol in nAMD and DME – When Time Is Sight (CME Track)
View More
Road Mapping the Treat-and-Extend Protocol in nAMD and DME – When Time Is Sight (COPE Track)
View More
Burst CME Plus™ - Unveiling Pharmacological Advances in nAMD & DME: From Durability to Applicability
View More
AcuFocus receives Approvable Letter from FDA for small aperture IOL
December 7th 2021The company will begin commercialization of the IC-8 small aperture IOL, used for cataract patients, upon successful completion of the manufacturing facility inspections and receipt of an official approval order from the FDA, which the company estimates in Q2 2022.
Read More
Mitomycin C increases corneal haze after corneal crosslinking
November 13th 2021Shady Awwad, MD, discusses how the application of mitomycin C after corneal crosslinking does not prevent development of corneal haze after the procedure and actually contributes to development of more corneal haze.
Read More
Landmark treatment: Cell therapy advances options for corneal endothelial disease
October 13th 2021Results from Aurion Biotech's IOTA trial reveals that a corneal endothelial cell therapy showed improvements in visual acuity and central corneal thickness, according to a team of Japanese investigators.
Read More
Assessing the severity of Fuchs’ endothelial corneal dystrophy by using Scheimpflug tomography
October 8th 2021Investigators sought to develop a severity scale for tomographic edema in FECD based on Scheimpflug tomography maps, and to evaluate intra- and inter-observer variation for assessing severity.
Read More
Researchers pioneer technology that leads successful clinical trial to treat dry eye disease
October 4th 2021A team of investigators at the Texas Tech University Health Sciences Center have developed a technology derived from corneal epithelial stem cells to improve outcomes for DED patients.
Read More
Deep learning for detection of keratoconus and prediction of CXL efficacy
September 24th 2021A study sought to implement and test a trained deep learning algorithm using pre-operative corneal topography scans in order to classify between keratoconus and normal corneas, stage the disease, and predict whether a patient will be likely to benefit from CXL treatment.
Read More
Considering keratoconus-like changes after DMEK in Fuchs' dystrophy
September 20th 2021A retrospective review was performed to describe changes in corneal thickness and to identify the incidence of posterior corneal changes characteristic of keratoconus, following DMEK surgery. Here’s what investigators found.
Read More